Tumor Necrosis Factor Receptor–Associated Factor 1 (TRAF1) Deficiency Attenuates Atherosclerosis in Mice by Impairing Monocyte Recruitment to the Vessel Wall
Authors:
- Natascha KösTlinNKNatascha KösTlin
- Nerea VaroNVNerea Varo
Open Access
- 11 May 2010
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 121 (18) , 2033-2044
Abstract
Background— Members of the tumor necrosis factor superfamily, such as tumor necrosis factor-α, potently promote atherogenesis in mice and humans. Tumor necrosis factor receptor–associated factors (TRAFs) are cytoplasmic adaptor proteins for this group of cytokines. Methods and Results— This study tested the hypothesis that TRAF1 modulates atherogenesis in vivo. TRAF1 −/− /LDLR −/− mice that consumed a high-cholesterol diet for 18 weeks developed significantly smaller atherosclerotic lesions than LDLR −/− (LDL receptor–deficient) control animals. As the most prominent change in histological composition, plaques of TRAF1-deficient animals contained significantly fewer macrophages. Bone marrow transplantations revealed that TRAF1 deficiency in both hematopoietic and vascular resident cells contributed to the reduction in atherogenesis observed. Mechanistic studies showed that deficiency of TRAF1 in endothelial cells and monocytes reduced adhesion of inflammatory cells to the endothelium in static and dynamic assays. Impaired adhesion coincided with reduced cell spreading, actin polymerization, and CD29 expression in macrophages, as well as decreased expression of the adhesion molecules intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in endothelial cells. Small interfering RNA studies in human cells verified these findings. Furthermore, TRAF1 messenger RNA levels were significantly elevated in the blood of patients with acute coronary syndrome. Conclusions— TRAF1 deficiency attenuates atherogenesis in mice, most likely owing to impaired monocyte recruitment to the vessel wall. These data identify TRAF1 as a potential treatment target for atherosclerosis.Keywords
This publication has 43 references indexed in Scilit:
- TRAF1–C5as a Risk Locus for Rheumatoid Arthritis — A Genomewide StudyNew England Journal of Medicine, 2007
- NF-κB2 mutation targets TRAF1 to induce lymphomagenesisBlood, 2007
- TRAF1 regulates recruitment of lymphocytes and, to a lesser extent, neutrophils, myeloid dendritic cells and monocytes to the lung airways following lipopolysaccharide inhalationImmunology, 2006
- Differential Functions of Tumor Necrosis Factor Receptor 1 and 2 Signaling in Ischemia-Mediated Arteriogenesis and AngiogenesisThe American Journal of Pathology, 2006
- Monocyte accumulation in mouse atherogenesis is progressive and proportional to extent of diseaseProceedings of the National Academy of Sciences, 2006
- TRAF1 regulates Th2 differentiation, allergic inflammation and nuclear localization of the Th2 transcription factor, NIP45International Immunology, 2005
- GRO family chemokines are specialized for monocyte arrest from flowAmerican Journal of Physiology-Heart and Circulatory Physiology, 2005
- Atherogenesis in Mice Does Not Require CD40 Ligand From Bone Marrow–Derived CellsArteriosclerosis, Thrombosis, and Vascular Biology, 2005
- Inflammation in atherosclerosisNature, 2002
- TRAF1 is a TNF inducible regulator of NF‐κB activationFEBS Letters, 1999